Evidence map›Paper›PMID 36230781›Full record

ReviewCancers2022

Potential Role of Sphingolipidoses-Associated Lysosphingolipids in Cancer.

Patricia Dubot, Leonardo Astudillo, Nicole Therville, Lorry Carrié, Magali Pettazzoni, David Cheillan, Jérôme Stirnemann, Thierry Levade, Nathalie Andrieu-Abadie, Frédérique Sabourdy

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Central Roles of Glucosylceramide in Driving Cancer Pathogenesis.International journal of molecular sciences · 2025
    Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Patricia DubotUniversité de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Equipe Labellisée Fondation ARC, 2 Avenue Hubert Curien, CS 53717, CEDEX 1, 31037 Toulouse, France.ORCID 0000-0002-9493-5338
Leonardo AstudilloUniversité de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Equipe Labellisée Fondation ARC, 2 Avenue Hubert Curien, CS 53717, CEDEX 1, 31037 Toulouse, France.
Nicole ThervilleUniversité de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Equipe Labellisée Fondation ARC, 2 Avenue Hubert Curien, CS 53717, CEDEX 1, 31037 Toulouse, France.ORCID 0000-0002-7068-1361
Lorry CarriéUniversité de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Equipe Labellisée Fondation ARC, 2 Avenue Hubert Curien, CS 53717, CEDEX 1, 31037 Toulouse, France.ORCID 0000-0003-1792-136X
Magali PettazzoniLaboratoire de Biochimie, Hospices Civils de Lyon, 69000 Bron, France.
David CheillanLaboratoire de Biochimie, Hospices Civils de Lyon, 69000 Bron, France.ORCID 0000-0001-9535-2567
Jérôme StirnemannDivision of General Internal Medicine, Department of Medicine, Geneva University Hospitals, 1211 Geneva, Switzerland.ORCID 0000-0001-9964-4452
Thierry LevadeUniversité de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Equipe Labellisée Fondation ARC, 2 Avenue Hubert Curien, CS 53717, CEDEX 1, 31037 Toulouse, France.
Nathalie Andrieu-AbadieUniversité de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Equipe Labellisée Fondation ARC, 2 Avenue Hubert Curien, CS 53717, CEDEX 1, 31037 Toulouse, France.ORCID 0000-0003-2698-1970
Frédérique SabourdyUniversité de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Equipe Labellisée Fondation ARC, 2 Avenue Hubert Curien, CS 53717, CEDEX 1, 31037 Toulouse, France.ORCID 0000-0003-4987-6823
Centre National de la Recherche Scientifique · FRHospices Civils de Lyon · FRUniversity Hospital of Geneva · CH

Funding

Inserm no grant number
6 · The paper itself

Abstract

Sphingolipids play a key structural role in cellular membranes and/or act as signaling molecules. Inherited defects of their catabolism lead to lysosomal storage diseases called sphingolipidoses. Although progress has been made toward a better understanding of their pathophysiology, several issues still remain unsolved. In particular, whether lysosphingolipids, the deacylated form of sphingolipids, both of which accumulate in these diseases, are simple biomarkers or play an instrumental role is unclear. In the meanwhile, evidence has been provided for a high risk of developing malignancies in patients affected with Gaucher disease, the most common sphingolipidosis. This article aims at analyzing the potential involvement of lysosphingolipids in cancer. Knowledge about lysosphingolipids in the context of lysosomal storage diseases is summarized. Available data on the nature and prevalence of cancers in patients affected with sphingolipidoses are also reviewed. Then, studies investigating the biological effects of lysosphingolipids toward pro or antitumor pathways are discussed. Finally, original findings exploring the role of glucosylsphingosine in the development of melanoma are presented. While this lysosphingolipid may behave like a protumorigenic agent, further investigations in appropriate models are needed to elucidate the role of these peculiar lipids, not only in sphingolipidoses but also in malignant diseases in general.

Indexed as

cancerGaucher diseaseglucosylsphingosinelysoGb3lysosulfatidemelanomapsychosinesphingolipidsphingosylphosphocholine

Identifiers

PMID36230781
PMCPMC9563581
OpenAlexW4303621981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.